Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Immuron (IMRN) EBITDA Margin (2016 - 2024)

Immuron's quarterly EBITDA Margin came in at 63.56% in Q4 2024, up 2220.0% year-on-year from 2.74% in Q1 2024, and up 25.88% quarter-over-quarter from 85.76% in Q4 2023.

Immuron has reported EBITDA Margin for 9 years, with the latest figure at 63.56% in Q4 2024.

  • For the quarter ending Q4 2024, EBITDA Margin rose 2220.0% year-over-year to 63.56%; the trailing twelve-month figure through Dec 2024 stood at 63.56% (up 72344.0% YoY), and the FY2025 full-year result was 72.66%, up 4472.0% from the prior year.
  • EBITDA Margin for Q4 2024 stood at 63.56%, up from 85.76% in the prior quarter.
  • The five-year high for EBITDA Margin was 313.07% in Q4 2022, with the low at 1494.83% in Q2 2023.
  • Average EBITDA Margin over 5 years is 417.63%, with a median of 236.12% recorded in 2020.
  • Year-over-year, EBITDA Margin tumbled 40173 bps in 2021 and jumped 110129 bps in 2022.
  • Tracing IMRN's EBITDA Margin over 5 years: stood at 386.48% in 2020, then slumped by 104 bps to 788.22% in 2021, then surged by 140 bps to 313.07% in 2022, then plunged by 127 bps to 85.76% in 2023, then gained by 26 bps to 63.56% in 2024.
  • The last three EBITDA Margin figures came in at 63.56% (Q4 2024), 85.76% (Q4 2023), and 1494.83% (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 18.35%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.24%
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -63.56%
Dec 31, 2023 -85.76%
Jun 30, 2023 -1,494.83%
Dec 31, 2022 313.07%
Dec 31, 2021 -788.22%
Dec 31, 2020 -386.48%
Dec 31, 2019 -97.59%
Dec 31, 2018 -161.98%
Dec 31, 2017 535.24%
Dec 31, 2016 481.82%
Jun 30, 2016 501.82%